DXED Peptide Inhibitors for Selective TSP-1 TGF-β1 Blocking
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current drug development targeting TGF-β for fibrosis and tumors faces challenges due to its multifunctionality and high toxicity, necessitating a safer strategy to inhibit TGF-β activation, particularly through TSP-1, to address fibrosis and cancer without interfering with normal physiological processes.
Innovation Solution
Development of short peptides with a DXED amino acid motif that inhibit TSP-1-dependent TGF-β1 activation, offering improved solubility, stability, and bioavailability, and minimizing interference with TSP-1's other functional domains.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If drugs directly target TGF-β and its signaling pathway, then fibrosis and tumor progression are inhibited, but toxicity increases due to interference with normal physiological processes
Solution Approach 1:
The patent segments the TGF-β activation process by targeting a specific activator (TSP-1) rather than the main TGF-β pathway itself. This segmentation allows inhibition of fibrosis and tumor progression while preserving normal physiological functions that rely on TGF-β signaling, thereby reducing toxicity.
Solution Approach 2:
The invention extracts and targets the specific function of TSP-1 as the activator of TGF-β1. By focusing on this specific activator domain, the drug can block TGF-β activation without interfering with TGF-β's normal physiological roles, thus separating the harmful effect (fibrosis/tumor promotion) from the beneficial effect (normal tissue maintenance).
2Ease of manufacture
If peptide length is reduced to improve cost-effectiveness, then manufacturing cost decreases, but binding affinity and activity may be compromised
Solution Approach 1:
The patent identifies and targets a specific local domain within TSP-1 that is critical for TGF-β activation. By focusing the peptide sequence on this specific functional domain rather than the entire protein, the invention achieves high binding affinity with a shortened peptide length, balancing cost-effectiveness with therapeutic reliability.
Data Source
AI summary
The present invention relates to a peptide inhibitor for inhibiting activation of TGF-β1 with the participation of TSP-1, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, and a pharmaceutical composition comprising the peptide or the pharmaceutically acceptable salt, solvate or prodrug thereof, and a method for treating or preventing TGF-β1 related diseases, in particular fibrosis and solid tumors, by using the peptide inhibitor or the pharmaceutically acceptable salt, solvate or prodrug thereof and the pharmaceutical composition.